Revolution Medicines Reports Q4 2025 Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy RVMD?
Source: seekingalpha
- Widening Net Loss: Revolution Medicines reported a net loss of $364.9 million for Q4 2025, significantly up from $194.6 million in Q4 2024, indicating ongoing high expenditures in R&D and operations that may pressure future financing capabilities.
- Stable Cash Reserves: As of December 31, 2025, the company held $2.0 billion in cash, cash equivalents, and marketable securities, maintaining strong liquidity despite increasing losses, which supports future operations and R&D initiatives.
- 2026 Financial Guidance: The company expects GAAP operating expenses for 2026 to range between $1.6 billion and $1.7 billion, including estimated non-cash stock-based compensation expenses of $180 to $200 million, which could impact profitability and investor confidence due to high spending levels.
- Negative Market Reaction: Following Merck's withdrawal from acquisition talks, Revolution Medicines' stock plummeted, exacerbating market concerns about its growth prospects and potentially leading to a reassessment of the company's strategic direction.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RVMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RVMD
Wall Street analysts forecast RVMD stock price to fall
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 102.020
Low
67.00
Averages
86.00
High
147.00
Current: 102.020
Low
67.00
Averages
86.00
High
147.00
About RVMD
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
REVOLUTION MEDICINES INC: UBS Increases Price Target from $71 to $145
- Price Increase Announcement: Revolution Medicines has raised the target price for its stock from $71 to $145.
- Market Impact: This significant increase reflects the company's positive outlook and potential growth in the market.
See More
Revolution Medicines Q4 2025 Earnings Call Highlights
- Pipeline Progress: Revolution Medicines has made substantial advancements in its RAS(ON) inhibitor pipeline, with four novel investigational drugs undergoing eight Phase III registrational trials and over 2,500 patients treated, indicating the company's potential and competitiveness in oncology.
- Financial Overview: As of Q4 2025, the company reported $2.03 billion in cash and investments, despite R&D expenses rising to $294.9 million year-over-year and a net loss of $364.9 million, reflecting high investments in clinical development and commercial preparations.
- Guidance Adjustment: The company shifted its financial outlook for 2026 from GAAP net loss to GAAP operating expenses, expecting these to range between $1.6 billion and $1.7 billion, highlighting its focus on expanding clinical programs and commercial readiness.
- Market Sentiment Caution: Analysts' scrutiny regarding trial design and interim data suggests a cautious market outlook on the company's future performance, although management expressed confidence in pipeline progress and commercial preparations during the earnings call.
See More
Revolution Medicines Reports Q4 2025 Financial Results
- Widening Net Loss: Revolution Medicines reported a net loss of $364.9 million for Q4 2025, significantly up from $194.6 million in Q4 2024, indicating ongoing high expenditures in R&D and operations that may pressure future financing capabilities.
- Stable Cash Reserves: As of December 31, 2025, the company held $2.0 billion in cash, cash equivalents, and marketable securities, maintaining strong liquidity despite increasing losses, which supports future operations and R&D initiatives.
- 2026 Financial Guidance: The company expects GAAP operating expenses for 2026 to range between $1.6 billion and $1.7 billion, including estimated non-cash stock-based compensation expenses of $180 to $200 million, which could impact profitability and investor confidence due to high spending levels.
- Negative Market Reaction: Following Merck's withdrawal from acquisition talks, Revolution Medicines' stock plummeted, exacerbating market concerns about its growth prospects and potentially leading to a reassessment of the company's strategic direction.
See More
Stock Movers: Nvidia, Paramount, First Solar, Workday, Axon, HP Inc., Lucid, and Others
- Stock Market Movement: Stock futures were rising on Wednesday, indicating positive investor sentiment.
- Response to Political Events: Investors appeared to overlook President Donald Trump’s State of the Union address, focusing instead on market trends.
See More
Revolution Medicines Set to Announce Q4 Earnings Results
- Earnings Announcement: Revolution Medicines is set to release its Q4 earnings on February 25th after market close, with a consensus EPS estimate of -$1.56, reflecting a significant 39.3% year-over-year decline, indicating ongoing challenges in profitability.
- Revenue Expectations: The consensus revenue estimate stands at $3.89 million, and despite the negative earnings outlook, the stability in revenue could provide some reassurance to investors amidst the volatility in the biotech sector.
- EPS Forecast Adjustments: Over the past three months, EPS estimates have seen two upward revisions with no downward adjustments, suggesting a slight increase in analyst confidence regarding the company's future performance, although the overall outlook remains negative.
- M&A Speculation: At a recent conference, Revolution Medicines declined to comment on the speculation surrounding its acquisition talks with Merck, which has walked away from negotiations, potentially impacting investor perceptions of the company's strategic direction.
See More
a16z Capital Management Acquires Navan Shares
- New Investment Highlight: According to the SEC filing dated February 17, 2026, a16z Capital Management acquired approximately 27 million shares of Navan in Q4 2025, with an estimated transaction value of $464.5 million, indicating strong confidence in Navan's future growth potential.
- Asset Allocation Shift: This acquisition positions Navan as 29.4% of a16z's reportable assets under management, reflecting its significant importance in the investment portfolio and potentially influencing future investment strategies.
- Market Performance Analysis: As of December 31, 2025, Navan's share price was $9.97, with a current market price of $10.23 and a market capitalization of $2.54 billion, showcasing market recognition of its technology-driven enterprise spend management platform.
- Business Model Transformation: Navan has evolved from a traditional travel booking tool to a comprehensive enterprise spend platform, integrating travel, payments, and expense management, thereby enhancing cost control and operational efficiency for businesses, attracting increased attention from corporate clients.
See More
REVOLUTION MEDICINES INC: UBS Increases Price Target from $71 to $145
- Price Increase Announcement: Revolution Medicines has raised the target price for its stock from $71 to $145.
- Market Impact: This significant increase reflects the company's positive outlook and potential growth in the market.
See More
Revolution Medicines Q4 2025 Earnings Call Highlights
- Pipeline Progress: Revolution Medicines has made substantial advancements in its RAS(ON) inhibitor pipeline, with four novel investigational drugs undergoing eight Phase III registrational trials and over 2,500 patients treated, indicating the company's potential and competitiveness in oncology.
- Financial Overview: As of Q4 2025, the company reported $2.03 billion in cash and investments, despite R&D expenses rising to $294.9 million year-over-year and a net loss of $364.9 million, reflecting high investments in clinical development and commercial preparations.
- Guidance Adjustment: The company shifted its financial outlook for 2026 from GAAP net loss to GAAP operating expenses, expecting these to range between $1.6 billion and $1.7 billion, highlighting its focus on expanding clinical programs and commercial readiness.
- Market Sentiment Caution: Analysts' scrutiny regarding trial design and interim data suggests a cautious market outlook on the company's future performance, although management expressed confidence in pipeline progress and commercial preparations during the earnings call.
See More
Revolution Medicines Reports Q4 2025 Financial Results
- Widening Net Loss: Revolution Medicines reported a net loss of $364.9 million for Q4 2025, significantly up from $194.6 million in Q4 2024, indicating ongoing high expenditures in R&D and operations that may pressure future financing capabilities.
- Stable Cash Reserves: As of December 31, 2025, the company held $2.0 billion in cash, cash equivalents, and marketable securities, maintaining strong liquidity despite increasing losses, which supports future operations and R&D initiatives.
- 2026 Financial Guidance: The company expects GAAP operating expenses for 2026 to range between $1.6 billion and $1.7 billion, including estimated non-cash stock-based compensation expenses of $180 to $200 million, which could impact profitability and investor confidence due to high spending levels.
- Negative Market Reaction: Following Merck's withdrawal from acquisition talks, Revolution Medicines' stock plummeted, exacerbating market concerns about its growth prospects and potentially leading to a reassessment of the company's strategic direction.
See More
Stock Movers: Nvidia, Paramount, First Solar, Workday, Axon, HP Inc., Lucid, and Others
- Stock Market Movement: Stock futures were rising on Wednesday, indicating positive investor sentiment.
- Response to Political Events: Investors appeared to overlook President Donald Trump’s State of the Union address, focusing instead on market trends.
See More
Revolution Medicines Set to Announce Q4 Earnings Results
- Earnings Announcement: Revolution Medicines is set to release its Q4 earnings on February 25th after market close, with a consensus EPS estimate of -$1.56, reflecting a significant 39.3% year-over-year decline, indicating ongoing challenges in profitability.
- Revenue Expectations: The consensus revenue estimate stands at $3.89 million, and despite the negative earnings outlook, the stability in revenue could provide some reassurance to investors amidst the volatility in the biotech sector.
- EPS Forecast Adjustments: Over the past three months, EPS estimates have seen two upward revisions with no downward adjustments, suggesting a slight increase in analyst confidence regarding the company's future performance, although the overall outlook remains negative.
- M&A Speculation: At a recent conference, Revolution Medicines declined to comment on the speculation surrounding its acquisition talks with Merck, which has walked away from negotiations, potentially impacting investor perceptions of the company's strategic direction.
See More
a16z Capital Management Acquires Navan Shares
- New Investment Highlight: According to the SEC filing dated February 17, 2026, a16z Capital Management acquired approximately 27 million shares of Navan in Q4 2025, with an estimated transaction value of $464.5 million, indicating strong confidence in Navan's future growth potential.
- Asset Allocation Shift: This acquisition positions Navan as 29.4% of a16z's reportable assets under management, reflecting its significant importance in the investment portfolio and potentially influencing future investment strategies.
- Market Performance Analysis: As of December 31, 2025, Navan's share price was $9.97, with a current market price of $10.23 and a market capitalization of $2.54 billion, showcasing market recognition of its technology-driven enterprise spend management platform.
- Business Model Transformation: Navan has evolved from a traditional travel booking tool to a comprehensive enterprise spend platform, integrating travel, payments, and expense management, thereby enhancing cost control and operational efficiency for businesses, attracting increased attention from corporate clients.
See More
